Furthermore, the overall cohort survival analyses showed that the expression of DSG2 predicted an unfavorable prognosis in bladder urothelial carcinoma (BLCA), brain lower-grade glioma (LGG), lung adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD) and uterine corpus endometrial carcinoma (UCEC), while predicting a favorable prognosis in colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) (all P < 0.05) (Fig. 2b). The gene discussed is DSG2; the disease is lung adenocarcinoma.